AGIOS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Current
AGIOS PHARMACEUTICALS, INC. (AGIO) had Debt Securities, Available-for-sale, Current of $517.93 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Current $517.93M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $623.44M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $765.29M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $860.15M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $517.93M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $623.44M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $765.29M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $860.15M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $858.07M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $814.41M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $817.46M 10-K · filed 2026-02-12 |
| 2024-09-30 | $751.03M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $485.37M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $479.23M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $688.72M 10-K · filed 2025-02-13 |
| 2023-09-30 | $583.15M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $617.81M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $635.06M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $643.86M 10-K · filed 2024-02-15 |
| 2022-09-30 | $605.23M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $730.77M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $843.50M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $816.89M 10-K · filed 2023-02-23 |
| 2021-03-31 | $447.58M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $445.49M 10-K · filed 2022-02-24 |
| 2020-09-30 | $500.68M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $494.27M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $439.53M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $483.95M 10-K · filed 2021-02-25 |
| 2018-12-31 | $514.80M 10-K · filed 2020-02-19 |
| 2016-12-31 | $380.56M 10-K · filed 2017-02-16 |
| 2016-09-30 | $293.60M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $231.32M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $273.86M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $245.24M 10-K · filed 2017-02-16 |
| 2015-09-30 | $272.32M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $297.26M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $309.45M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $328.03M 10-K · filed 2016-02-26 |
| 2014-09-30 | $149.92M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $130.23M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $129.43M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $95.21M 10-K · filed 2015-02-24 |
| 2012-12-31 | $36.68M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |